Abstract: The present invention concerns methods and compositions for treating or preventing a fungal infection, particularly infection by a Coccidioides species. The invention provides methods and compositions for stimulating an immune response against the fungus. In certain embodiments, the methods and compositions involve a recombinant vaccine.
Type:
Grant
Filed:
March 22, 2019
Date of Patent:
August 16, 2022
Assignees:
Board of Regents, The University of Texas System, The University of Massachusetts
Inventors:
Chiung-Yu Hung, Gary Ostroff, Natalia Castro-Lopez
Abstract: Apparatus and methods for imaging a region of a subject comprising an artifact. In certain embodiments, the apparatus and methods utilize computed tomography (CT) scans obtained at two different angles to image a region posterior to an artifact.
Type:
Application
Filed:
June 10, 2020
Publication date:
August 11, 2022
Applicant:
Board of Regents, The University of Texas System
Inventors:
David FOLLOWILL, Stephen KRY, Daniela BRANCO
Abstract: Provided herein are methods for the treatment of brain metastasis by administering a kinase inhibitor targeted to a metastasis-promoting kinase identified by an in vivo kinase screen.
Type:
Grant
Filed:
August 10, 2018
Date of Patent:
August 9, 2022
Assignee:
Board of Regents, The University of Texas System
Inventors:
Dihua Yu, Frank Lowery, Chenyu Zhang, Sunil Acharya, Ping Li
Abstract: Stable perfluorocarbon nanodroplet compositions with properties such as low-boiling points and small particle diameters are provided for improved performance in ultrasound imaging and therapeutic applications. Methods of producing stabilized nanodroplet compositions and methods of using the compositions are further provided to allow for improved performance in ultrasound imaging techniques and/or therapeutic applications.
Type:
Grant
Filed:
March 16, 2018
Date of Patent:
August 9, 2022
Assignee:
The Board of Regents of The University of Texas System
Inventors:
Caroline de Gracia Lux, Jacques Lux, Alexander M. Vezeridis, Robert F. Mattrey
Abstract: A dielectric elastomer system (DES) variable stiffness actuator (VSA) is provided. In an embodiment, the DES VSA includes a variable stiffness module (VSM). The VSM includes a DES that softens when energized and stiffens when unpowered, an outer frame, and an inner frame member. The stiffness of the DES is variable. The outer frame supports the DES and the inner frame member, which is disposed within the DES. The inner frame member is configured to be displaceable with respect to the outer frame. The DES VSA also includes an actuation motor mechanically coupled to the inner frame member that is configured to cause a force to be applied to the inner frame member and the actuation motor is configured to control an equilibrium position of the DES VSA.
Type:
Grant
Filed:
December 15, 2020
Date of Patent:
August 9, 2022
Assignee:
Board of Regents, The University of Texas System
Inventors:
Robert D. Gregg, IV, Edgar A. Bolivar, David P. Allen, Walter E. Voit
Abstract: A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3?-indoline]-2?,5(3H)-dione analogues, the use thereof and the preparation thereof.
Type:
Grant
Filed:
July 24, 2020
Date of Patent:
August 9, 2022
Assignee:
The Board of Regents of The University of Texas System
Abstract: Small molecule disruptors of Beclin-1/Bc1-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.
Type:
Application
Filed:
April 5, 2022
Publication date:
August 4, 2022
Applicant:
Board of Regents, The University of Texas System
Inventors:
Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
Abstract: Certain embodiments are directed to methods of treating autoimmune disorders by administering P2 purnergic receptor antagonist and/or adenosine receptor antagonists. The P2 purnergic receptor antagonist being chemical analogs of adenosine receptor antagonist 8-Ethoxy-9-ethyl-9H-purin-6-amine. The adenosine receptor antagonists being chemical analogs of the non-hydrolysable ATP analog adenosine 5?[?-thio]triphosphate (ATP?S). Certain embodiments are directed to the use of the chemical analogs to modulate IL-17 activity.
Type:
Grant
Filed:
October 19, 2018
Date of Patent:
August 2, 2022
Assignee:
Board of Regents, The University of Texas System
Abstract: Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.
Type:
Grant
Filed:
October 7, 2020
Date of Patent:
August 2, 2022
Assignee:
Board of Regents, The University of Texas System
Inventors:
Maria Emilia Di Francesco, Philip Jones, Michael A. Curran
Abstract: A machine learning system efficiently detects faults from three-dimensional (ā3Dā) seismic images, in which the fault detection is considered as a binary segmentation problem. Because the distribution of fault and nonfault samples is heavily biased, embodiments of the present disclosure use a balanced loss function to optimize model parameters. Embodiments of the present disclosure train a machine learning system by using a selected number of pairs of 3D synthetic seismic and fault volumes, which may be automatically generated by randomly adding folding, faulting, and noise in the volumes. Although trained by using only synthetic data sets, the machine learning system can accurately detect faults from 3D field seismic volumes that are acquired at totally different surveys.
Type:
Grant
Filed:
November 25, 2020
Date of Patent:
August 2, 2022
Assignee:
Board of Regents, The University of Texas System
Abstract: The present invention relates to quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT), the preparation thereof and uses thereof. Formula (I).
Type:
Grant
Filed:
March 29, 2018
Date of Patent:
August 2, 2022
Assignee:
The Board of Regents of The University of Texas System
Inventors:
Stanley Watowich, Harshini Neelakantan, Hua-Yu Wang, Stanton Mchardy
Abstract: Methods for reversing one or more mutations in the telomerase (TERT) promoter are provided and may be used to treat a cancer. In some embodiments, programmable base editing (PBE) is used to correct a mutated TERT promoter (e.g., ?124 C>T, ?228C>T, or ?250C>T to ?124 C, ?228C, or ?250C, respectively) by using a single guide (sg) RNA-guided and deactivated Campylobacter jejuni Cas9-fused adenine base editor (CjABE). These methods can be used to treat a cancer, such as for example glioblastoma multiforme (GBM), in a mammalian subject in vivo.
Type:
Application
Filed:
May 15, 2020
Publication date:
July 28, 2022
Applicants:
Board of Regents, The University of Texas System, Tsinghua University
Inventors:
Zhimin LU, Ronald DEPINHO, Dongming XING
Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Type:
Application
Filed:
April 1, 2022
Publication date:
July 28, 2022
Applicant:
The Board of Regents of The University of Texas System
Inventors:
Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
Abstract: The present disclosure provides methods for generating Otub 1 deficient T cells and natural killer (NK) cells and compositions comprising engineered T cells expressing a reduced amount of Otub 1. Further provided are methods of treating cancer comprising administering the Otub 1 deficient T cells and/or NK cells to a subject in need thereof.
Type:
Application
Filed:
May 7, 2020
Publication date:
July 28, 2022
Applicant:
Board of Regents, The University of Texas System
Abstract: Provided herein are methods and compositions for the treatment of cancer by modulating the microbiome to enhance the efficacy of immune checkpoint blockade. The microbiome may be modulated by the administration of butyrate and/or butyrate-producing bacteria. Also provided herein are methods of determining a response to an immune checkpoint inhibitor by identifying if a subject has a favorable microbial profile.
Type:
Grant
Filed:
September 27, 2017
Date of Patent:
July 26, 2022
Assignee:
Board of Regents, The University of Texas System
Inventors:
Jennifer Wargo, Vancheswaran Gopalakrishnan
Abstract: A method of monitoring a condition of a SiC MOSFET can include (a) applying a first test gate-source voltage across a gate-source of a SiC MOSFET in-situ, the first test gate-source voltage configured to operate the SiC MOSFET in saturation mode to generate a first drain current in the SiC MOSFET, (b) applying a second test gate-source voltage across the gate-source of the SiC MOSFET in-situ, the second test gate-source voltage configured to operate the SiC MOSFET in fully-on mode to generate a second drain current in the SiC MOSFET, (c) determining a drain-source saturation resistance using the first drain current to provide an indication of a degradation of a gate oxide of the SiC MOSFET; and (d) determining a drain-source on resistance using the second drain current to provide an indication of a degradation of contact resistance of the SiC MOSFET.
Type:
Grant
Filed:
June 10, 2020
Date of Patent:
July 26, 2022
Assignee:
Board of Regents, The University of Texas System
Inventors:
Bilal Akin, Shi Pu, Enes Ugur, Fei Yang, Chi Xu, Bhanu Teja Vankayalapati
Abstract: A system and method estimate the fault severity index and consequently the number of shorted turns in permanent magnet motors (PMSM) with inter turn short circuit fault (ITSC). In this method, the machine is excited with DC current at stand still conditions to obtain the winding resistance seen by the d-axis of the machine. The estimated d-axis resistance contains useful information pertaining to the fault severity index, and is used to extract the fault severity index and the number of shorted turns in the faulty motor. The method enables the estimation of fault severity index without complex modeling with different machine prototypes, or FEA models to analyze the relationship between machine currents and short circuit current. To enhance the accuracy of the estimation method, this disclosure addresses issues associated with inverter non-linearity effects such as distortion voltage due to dead time effects and voltage drops across the switching devices.
Type:
Application
Filed:
January 20, 2021
Publication date:
July 21, 2022
Applicant:
Board of Regents, The University of Texas System
Abstract: Described herein are pH responsive compounds, micelles, and compositions useful for the detection of primary and metastatic tumor tissues. Compounds described herein are imaging agents useful for the detection of primary and metastatic tumor tissue (including lymph nodes). Real-time fluorescence imaging during surgery aids surgeon in the detection of metastatic lymph nodes or delineate tumor tissue versus normal tissue, with the goal of achieving negative margins and complete tumor resection.
Type:
Application
Filed:
May 28, 2020
Publication date:
July 21, 2022
Applicant:
The Board of Regents of The University of Texas System
Inventors:
Jinming GAO, Baran SUMER, Tian ZHAO, Zachary T. BENNETT
Abstract: The disclosure provides methods and compositions for inhibiting pain and comorbid cognitive deficits by administering a MNK inhibitor to a subject in need thereof. Also provided are methods of using the inhibitor in combination with other pain therapies.
Type:
Application
Filed:
May 22, 2020
Publication date:
July 21, 2022
Applicant:
Board of Regents, The University of Texas System
Abstract: The present disclosure provides radiolabeled compounds of the formula: (I) and (II), as well as precursor compounds of the formula: (VII) wherein the variables are defined herein. The present disclosure also provides radiopharmaceutical compositions comprising the radiolabeled compounds disclosed herein as well as precursor compositions comprising the precursor compounds disclosed herein. The present disclosure further provides methods of imaging using the radiolabeled compounds and/or radiopharmaceutical compositions of the present disclosure as well as kits for the preparation of the radiolabeled compounds and radiopharmaceutical compositions disclosed herein.
Type:
Application
Filed:
April 16, 2020
Publication date:
July 14, 2022
Applicant:
Board of Regents, The University of Texas System
Inventors:
David PIWNICA-WORMS, Federica PISANESCHI, Seth GAMMON